Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell cycle and gene profile.  MDA-MB231 cells showed more sensitivity to imatinib mesylate than to dipyridamole, with an IC50 value of 348 g/mL versus 494 g/mL for imatinib mesylate and dipyridamole, respectively (P-value < 0.05). The up/downregulation of Bax and Bcl-2 and metastasis contributing gene (MMP-1) assured the anticancer activity. Also, the apoptotic potential of dipyridamole and imatinib mesylate was verified by arresting cells in the G2/M phase and increasing the percentage of the apoptotic cells in the pre-G1 phase. The antioxidant levels were drug dependent, as they were significantly higher(P<0.05)  in cells treated with imatinib than in cells treated with Dipyridamole.
Conclusion: Imatinib mesylate growth-inhibitory impact on breast cell lines, either alone or in combination with dipyridamole, may be mediated through up/downregulation of the Bax, Bcl-2, and MMP-1 genes. Imatinib is a promising treatment for breast cancer patients who require targeted therapy.